Table 3.
Literature Search Results Showing Changes in PHQ-9 Scores After the Initiation of ELX/TEZ/IVA Treatment in People with CF
| Author, Year (Reference No.) | Country | Age | N | Follow-up Assessment Duration After ELX/TEZ/IVA Treatment | Change in PHQ-9 Scores After ELX/TEZ/IVA Initiation |
|---|---|---|---|---|---|
| Borawska-Kowalczyk, 2023 (36) | Poland | Not specified (abstract) | 52 | 3 mo | No change |
| Ergenekon, 2023 (37) | Turkey | 11–22 yr (median, 18 yr) | 86 | 6 mo | Decrease |
| Graziano, 2023 (38) | Italy | 12–59 yr (mean, 25.4 yr) | 92 | 1, 3, and 6 mo | Decrease |
| Piehler, 2023 (33) | Germany | Median, 27.9 yr (IQR, 22.5–34.1) | 70 | 2–4 mo | Decrease |
| Blackwelder, 2022 (39) | United States | Adult | 172 | 12 mo | Decrease |
| Zhang, 2022 (40) | United States | Mean, 35.3 ± 11.3 yr | 100 | 12 mo | No change |
| Vance, 2021 (41) | United States | 12–20 yr | 62 | 3, 6, 9, and 12 mo | No change |
| Pudukodu, 2021 (42) | United States | ⩾18 yr | 39 | Not specified | No change |
| George, 2020 (43) | United States | Pediatric | 14 | 1, 3, and 6 mo | Decrease |
| Sakon, 2022 (35) | United States | Mean, 29 ± 12 yr | 56 | 3–6 mo | Decrease (median: −1.11) |
| Dell, 2022 (44) | United States | Adolescents and adults | 184 | 1, 3, 6, 9, and 12 mo | Decrease |
| Allgood, 2021 (45) | United States | Median, 35.6 yr | 24 | 98 d | No change |
Definition of abbreviations: CF = cystic fibrosis; ELX/TEZ/IVA = elexacaftor/tezacaftor/ivacaftor; IQR = interquartile range; PHQ-9 = nine-item Patient Health Questionnaire.
A literature search identified published studies (n = 3) and congress presentations (n = 9) that used the PHQ-9 assessment tool to evaluate changes in depression symptoms after starting ELX/TEZ/IVA treatment.